Activation of the hypoxia‐inducible factor pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Hypoxia‐inducible transcription factors (HIF) mediate complex adaptations to reduced oxygen supply, including neoangiogenesis. Regulation of HIF occurs mainly through oxygen‐dependent destruction of its α subunit. In the presence of oxygen, two HIFα prolyl residues undergo enzymatic hydroxylation, which is required for its proteasomal degradation. We therefore tested whether pharmacological activation of HIFα by hydroxylase inhibitors may provide a novel therapeutic strategy for the treatment of ischemic diseases. Three distinct prolyl 4‐hydroxylase inhibitors— l ‐mimosine ( l ‐Mim), ethyl 3,4‐dihydroxybenzoate (3,4‐DHB), and 6‐chlor‐3‐hydroxychinolin‐2‐carbonic acid‐N‐carboxymethylamid (S956711)—demonstrated similar effects to hypoxia (0.5% O 2 ) by inducing HIFα protein in human and rodent cells. l ‐Mim, S956711, and, less effectively, 3,4‐DHB also induced HIF target genes in cultured cells, including glucose transporter 1 and vascular endothelial growth factor, as well as HIF‐dependent reporter gene expression. Systemic administration of l ‐Mim and S956711 in rats led to HIFα induction in the kidney. In a sponge model for angiogenesis, repeated local injection of the inhibitors strongly increased invasion of highly vascularized tissue into the sponge centers. In conclusion, structurally distinct inhibitors of prolyl hydroxylation are capable of inducing HIFα and HIF target genes in vitro and in vivo and induce adaptive responses to hypoxia, including angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535 · cited 3×
“21 mM in vitro and in cultured cells (5, 7).”
BackgroundMethodThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Self-citationHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002) · Science · doi:10.1126/science.1068592 · Cited by 1,558 · cited 1×
“In the present study, therefore, we used a pharmacological approach to stabilize HIF, based on the elucidation of enzymatic prolyl (57) and asparagyl hydroxylation (11, 36) as the oxygen sensor mechanism responsible for HIF stabilization and activation.”
MethodLando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550
Mahon, P. C., Hirota, K., & Semenza, G. L. (2001) · Genes & Development · doi:10.1101/gad.924501 · Cited by 1,385
Wenger, R. H. (2002) · The FASEB Journal · doi:10.1096/fj.01-0944rev · Cited by 1,135
Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.18.5197 · Cited by 1,014 · cited 1×
“21 mM in vitro and in cultured cells (5, 7).”
BackgroundSelf-citation
Cited by
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068
Chronic Hypoxia and Tubulointerstitial Injury: A Final Common Pathway to End-Stage Renal Failure
Nangaku, M. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005070757 · Cited by 1,135
Weidemann, A., & Johnson, R. S. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.12 · Cited by 941
Self-citationHIF-1α expression regulates the bactericidal capacity of phagocytes
Peyssonnaux, C., Datta, V., Cramer, T., Doedens, A., Theodorakis, E. A., Gallo, R. L., Hurtado-Ziola, N., Nizet, V., & Johnson, R. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23865 · Cited by 702
Bruick, R. K. (2003) · Genes & Development · doi:10.1101/gad.1145503 · Cited by 440
Role and regulation of prolyl hydroxylase domain proteins
Fong, G.-H., & Takeda, K. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.10 · Cited by 427
Inhibition of 2-oxoglutarate dependent oxygenases
Rose, N. R., McDonough, M. A., King, O. N. F., Kawamura, A., & Schofield, C. J. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00203h · Cited by 390
Molecular Biology of Erythropoietin
JELKMANN, W. (2004) · Internal Medicine · doi:10.2169/internalmedicine.43.649 · Cited by 383
Farrow, E. G., Yu, X., Summers, L. J., Davis, S. I., Fleet, J. C., Allen, M. R., Robling, A. G., Stayrook, K. R., Jideonwo, V., Magers, M. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110905108 · Cited by 380
Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases
Eltzschig, H. K., Bratton, D. L., & Colgan, S. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4422 · Cited by 366
Baranova, O., Miranda, L. F., Pichiule, P., Dragatsis, I., Johnson, R. S., & Chavez, J. C. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0449-07.2007 · Cited by 350
Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
Bernhardt, W. M., Wiesener, M. S., Scigalla, P., Chou, J., Schmieder, R. E., Günzler, V., & Eckardt, K.-U. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010116 · Cited by 340
Self-citationNANGAKU, M. (2004) · Internal Medicine · doi:10.2169/internalmedicine.43.9 · Cited by 336
Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease
Fraisl, P., Aragonés, J., & Carmeliet, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2761 · Cited by 326
Modulation of Shigella virulence in response to available oxygen in vivo
Marteyn, B., West, N. P., Browning, D. F., Cole, J. A., Shaw, J. G., Palm, F., Mounier, J., Prévost, M.-C., Sansonetti, P., & Tang, C. M. (2010) · Nature · doi:10.1038/nature08970 · Cited by 322
miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target
Serocki, M., Bartoszewska, S., Janaszak-Jasiecka, A., Ochocka, R. J., Collawn, J. F., & Bartoszewski, R. (2018) · Angiogenesis · doi:10.1007/s10456-018-9600-2 · Cited by 288
Preconditional Activation of Hypoxia-Inducible Factors Ameliorates Ischemic Acute Renal Failure
Bernhardt, W. M., Ca[Combining Circumflex Accent]mpean, V., Kany, S., Ju[Combining Diaeresis]rgensen, J.-S., Weidemann, A., Warnecke, C., Arend, M., Klaus, S., Gu[Combining Diaeresis]nzler, V., Amann, K., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121302 · Cited by 295
Self-citationHypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition
Siddiq, A., Ayoub, I. A., Chavez, J. C., Aminova, L., Shah, S., LaManna, J. C., Patton, S. M., Connor, J. R., Cherny, R. A., Volitakis, I., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504963200 · Cited by 282
Hill, P., Shukla, D., Tran, M. G. B., Aragones, J., Cook, H. T., Carmeliet, P., & Maxwell, P. H. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006090998 · Cited by 282
Role of hypoxia in the pathogenesis of renal disease
Eckardt, K.-U., Bernhardt, W. W., Weidemann, A., Warnecke, C., Rosenberger, C., Wiesener, M. M., & Willam, C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09909.x · Cited by 277
Self-citationMyllyharju, J. (2008) · Annals of Medicine · doi:10.1080/07853890801986594 · Cited by 267
Prigione, A., Rohwer, N., Hoffmann, S., Mlody, B., Drews, K., Bukowiecki, R., Blümlein, K., Wanker, E. E., Ralser, M., Cramer, T., et al. (2014) · Stem Cells · doi:10.1002/stem.1552 · Cited by 254
Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing
Webb, J. D., Coleman, M. L., & Pugh, C. W. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0147-7 · Cited by 253
Takeda, K., Cowan, A., & Fong, G.-H. (2007) · Circulation · doi:10.1161/circulationaha.107.701516 · Cited by 236
Hsieh, M. M., Linde, N. S., Wynter, A., Metzger, M., Wong, C., Langsetmo, I., Lin, A., Smith, R., Rodgers, G. P., Donahue, R. E., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073254 · Cited by 171
Okumura, C. Y. M., Hollands, A., Tran, D. N., Olson, J., Dahesh, S., von Köckritz-Blickwede, M., Thienphrapa, W., Corle, C., Jeung, S. N., Kotsakis, A., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0882-3 · Cited by 115
“1a, [29, 30]).”
Barrett, T. D., Palomino, H. L., Brondstetter, T. I., Kanelakis, K. C., Wu, X., Haug, P. V., Yan, W., Young, A., Hua, H., Hart, J. C., et al. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.070508 · Cited by 78
“A collection of other compounds, including inhibitors of the related dioxygenase enzyme procollagen prolyl 4-hydroxylase such as 3,4-dihydroxybenzoate (Warnecke et al., 2003), clioquinol (Choi et al.”
BackgroundAyrapetov, M. K., Xu, C., Sun, Y., Zhu, K., Parmar, K., D'Andrea, A. D., & Price, B. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026064 · Cited by 41
Associations between HIFs and tumor immune checkpoints: mechanism and therapy
Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13
“In terms of clinical development, PHD3 inhibitors are the most advanced [110–112].”
Background
Metadata
- Authors
- Warnecke, C., Griethe, W., Weidemann, A., Jürgensen, J. S., Willam, C., Bachmann, S., Ivashchenko, Y., Wagner, I., Frei, U., Wiesener, M., & Eckardt, K.-U.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2003-04-22
- Volume
- 17
- Issue
- 9
- Pages
- 1186-1188
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2079844104
- Cited by
- 200
- References
- 14
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.